Transcriptomics,Genomics

Dataset Information

25

Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations


ABSTRACT: Abstract: Most GISTs require oncogenic activation of the KIT or PDGFRA receptor tyrosine kinase proteins, and the genomic mechanisms of oncogene activation are heterogeneous. Notably, the kinase mutation type correlates with both tumor biology and imatinib response. For example, GISTs with KIT exon 11 mutations are typically gastric and have excellent imatinib response, whereas those with KIT exon 9 mutations generally arise in the small bowel and are less responsive to imatinib. To identify genes that might contribute to these biological differences, we carried out gene expression profiling of 26 GISTs with known KIT and PDGFRA mutational status. Expression differences were then evaluated further by RNA in situ hybridization, immunohistochemistry, and immunoblotting. Unsupervised hierarchical clustering grouped tumors with similar mutations together, but the distinction between the different groups was not absolute. Differentially expressed genes included ezrin, p70S6K, and PKCs, which are known to have key roles in KIT or PDGFRA signaling, and which might therefore contribute to the distinctive clinicopathological features in GISTs with different mutation types. These gene products could serve as highly selective therapeutic targets in GISTs containing the KIT or PDGFRA mutational types with which they are associated. A disease state experiment design type is where the state of some disease such as infection, pathology, syndrome, etc is studied. Keywords: disease_state_design Overall design: Computed

INSTRUMENT(S): SHCX

SUBMITTER: Stanford Microarray Database  

PROVIDER: GSE4001 | GEO | 2006-01-10

SECONDARY ACCESSION(S): PRJNA95215

REPOSITORIES: GEO

altmetric image

Publications


Most GISTs require oncogenic activation of the KIT or PDGFRA receptor tyrosine kinase proteins, and the genomic mechanisms of oncogene activation are heterogeneous. Notably, the kinase mutation type correlates with both tumor biology and imatinib response. For example, GISTs with KIT exon 11 mutations are typically gastric and have excellent imatinib response, whereas those with KIT exon 9 mutations generally arise in the small bowel and are less responsive to imatinib. To identify genes that mi  ...[more]

Similar Datasets

2013-06-14 | E-GEOD-47911 | ArrayExpress
| GSE93077 | GEO
2013-06-14 | E-GEOD-47912 | ArrayExpress
| PRJNA95215 | ENA
2010-06-30 | GSE14755 | GEO
2010-06-30 | E-GEOD-14755 | ArrayExpress
2015-01-08 | E-GEOD-64762 | ArrayExpress
2010-04-13 | E-GEOD-21315 | ArrayExpress
2010-04-13 | GSE21315 | GEO
2009-09-05 | E-GEOD-17743 | ArrayExpress